# intoDNA

Source: https://onco.cc/companies/intodna/  
OnCo record `intodna` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Krakow spin-out from the Jagiellonian University whose STRIDE assay counts individual DNA breaks in cells, sold to drug developers and aimed at predicting who responds to DNA-repair drugs.

## Summary

intoDNA was founded in 2016 by researchers from the Jagiellonian University in Krakow to commercialise STRIDE, a fluorescence method that detects single- and double-strand DNA breaks directly in fixed cells. The company offers STRIDE as a contract research service to pharmaceutical and biotech companies developing DNA damage response drugs, radiosensitisers and chemotherapy combinations, and is working towards a functional companion test for PARP inhibitor response.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: intoDNA S.A.
- HQ: Krakow, Poland
- Type: biotech
- Website: https://intodna.com

## Sources

- Official website: https://intodna.com

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [HRD & BRCA testing](https://onco.cc/technologies/hrd-testing/), [RAD51 foci assay (functional HRD test)](https://onco.cc/technologies/rad51-foci-assay/), [STRIDE DNA break detection (intoDNA)](https://onco.cc/technologies/stride-dna-break-detection/)

---
JSON: https://onco.cc/api/v1/entities/intodna.json